Ty-Jour T1 - 广泛使用结核病血清学试验：来自22个高负荷国家的数据JF - 欧洲呼吸杂志Jo - Eur Respir J SP - 502 LP - 505 Do - 10.1183 / 09031936.00070611 VL - 39是 - 2 Au - Grenier，J.Au - Pinto，L. Au - Nair，D. Au - Steingart，K.Au - Dowdy，D. Au - Ramsay，A. Au - Pai，M. Y1 - 2012/02 / 01 UR - HTTP：//www.qdcxjkg.com/content/39/2/502.Abstract n2 - 向编辑：对新结核病（TB）诊断的引入有很大的兴奋[1]。自2007年以来，世界卫生组织（WHO）[2]批准了几个结核病诊断和方法，XPERT MTB / RIF（Cepheid，Sunnyvale，CA，USA）是最近的[3]。在这种兴奋中，围绕使用不适当的和次优的TB诊断，越来越多的令人担忧[4,5]。用于Tb的可用商业血清学（抗体检测）测试是不准确的，高度不一致[6-8]。TB护理的国际标准明确阻止他们的使用[9]。即便如此，已知血清学测试在印度（如4,4,5）等国家广泛使用。In addition to posing an economic burden on patients and healthcare systems, use of serological tests also entails potential harm to patients (e.g. unnecessary TB therapy because of false-positive results, or morbidity and mortality because of false-negative serology results).After reviewing the evidence, including the findings of an updated meta-analysis [10], the WHO recently announced its first negative policy in TB, against the use of current TB serological tests [5 … ER -